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Tuberculosis (TB) is one of the leading causes of death due to an infectious disease in the world. Un-
derstanding the mechanisms of drug resistance has become pivotal in the detection and treatment of
newly emerging resistant TB cases. We have analyzed three pairs of Mycobacterium tuberculosis strains
pre- and post-drug treatment to identify mutations involved in the progression of resistance to the drugs
rifampicin and isoniazid. In the rifampicin resistant strain, we conﬁrmed a mutation in rpoB (S450L) that
is known to confer resistance to rifampicin. We discovered a novel L101R mutation in the katG gene of an
isoniazid resistant strain, which may directly contribute to isoniazid resistance due to the proximity of
the mutation to the katG isoniazid-activating site. Another isoniazid resistant strain had a rare mutation
in the start codon of katG. We also identiﬁed a number of mutations in each longitudinal pair, such as
toxineantitoxin mutations that may inﬂuence the progression towards resistance or may play a role in
compensatory ﬁtness. These ﬁndings improve our knowledge of drug resistance progression during
therapy and provide a methodology to monitor longitudinal strains using whole genome sequencing,
polymorphism comparison, and functional annotation.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Along with HIV, Tuberculosis (TB) is the leading causes of death
due to an infectious disease, with an estimated 1.5 million deaths
per year [1]. In 2014, the disease infected an estimated 9.6 million
people around theworld, with about 3.6million of those people not
getting proper treatment [1]. In recent years, inappropriate appli-
cations of frontline antibiotic therapies have created an upsurge in
the emergence of multiple drug-resistant (MDR) and extensively
drug-resistant (XDR) strains of Mycobacterium tuberculosis (Mtb)
[2]. MDR TB is deﬁned as resistance to Isoniazid (INH) and, 1400 Jackson Street, Denver,
Datta), luisa.nieto_ramirez@
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Ltd. This is an open access article uRifampicin (RIF), and XDR TB is resistant to INH, RIF, any Fluo-
roquinolone, and any of the three second-line injectables (Amika-
cin, Capreomycin or Kanamycin) [1]. In 2014, there were an
estimated 480,000 MDR TB cases and the World Health Organiza-
tion received reports of 123,000 of these cases [1]. An estimated
9.7% of MDR TB cases were XDR instances [1]. The current treat-
ment initiatives for MDR TB involve a combination therapy of 8e10
drugs for 18e24 months with serious side effects and result in
nearly 30% of the patients experiencing treatment failure [3]. RIF
and INH are the two main ﬁrst line drugs used to treat TB and there
has been increasing emergence of strains resistant to both [4]. INH
is a bactericide that inhibits dividing bacilli and is used in short-
course treatment regimens in TB [5]. Mutations in the gene katG
that prohibit activation of INH are the primary cause of resistance to
the drug in TB [5]. Mutations in the b subunit of RNA polymerase of
Mtb (rpoB) inhibit binding of RIF to the RNA polymerase, thus
introducing resistance [4]. RpoB mutations account for over 95% of
strains with RIF resistance [4].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ment of initially drug-sensitive disease or the acquisition of already
resistant strains [5]. Acquired drug resistance happens during
treatment, and is typically a result of single nucleotide poly-
morphisms (SNPs) in genes that encode target proteins or drug
activating enzymes [4,6]. After certain mutation-conferring resis-
tance events occur, Mtb strains are sometimes able to optimize
ﬁtness and evolve mutations that confer the highest drug resis-
tance with the lowest ﬁtness cost [7]. Understanding the mecha-
nisms of drug resistance has become important in correctly
diagnosing and treating MDR TB. Clinical drug-resistant TB is pri-
marily diagnosed by phenotypic drug-susceptibility testing on
slowly-growing Mtb cultures [2]. This process can take several
weeks, and the lag can result in improper treatment leading to
higher mortality and transmission rates of drug-resistant strains
[2]. Current genotypic susceptibility testing techniques forMtb can
only elucidate resistance proﬁles based on known mutations [8].
Therefore, there is a need to develop efﬁcient strategies to elucidate
the mechanisms of drug resistance and generate faster resistance
proﬁles for novel strains using molecular means [2,9].
Whole genome sequencing has been used to identify novel
mutations for resistance in bacteria and to elucidate mutation
rates in TB [6,10e14]. In this paper, we describe the genomic an-
alyses of three pairs of pre- and post-drug treatment strains of
Mtb. These strain pairs are representative of drug resistance evo-
lution in patients due to drug therapy. Two pairs evolved resis-
tance to INH, and the third evolved resistance to RIF. We identify
mutations in rpoB and katG that likely explain the acquisition of
resistance in clinical strains of Mtb. Identiﬁcation of these poly-
morphisms, and the adoption of similar genomic analysis pipe-
lines, will aid in the diagnosis and monitoring of drug resistance in
new Mtb strains, thus improving treatment of TB. We also identify
mutations in genes that may contribute to the ﬁtness or drug
tolerance of the strains.
2. Materials and methods
2.1. Mtb strains
All Mtb strains were obtained from patients being treated for
active pulmonary TB. Isolates were sent to National Jewish Health,
Denver, CO, for conﬁrmation of drug susceptibility data initially
obtained by the patient's primary clinical lab. Clinical isolates C26-
RIFs and C22-RIFr of the Beijing genetic subgroup representing one
pan susceptible (C26-RIFs) and one RIF resistant (C22-RIFr) isolate
were used for this study (details regarding this pair were reported
previously) (Supp. table 1) [4]. Clinical isolate C4-INHs presented
susceptibility to all drugs tested (RIF, INH, pyrazinamide, and
ethambutol) and was obtained from a patient living in Spain prior
to initiating anti-tubercular therapy (Supp. table 1). Clinical isolate
C1-INHr was later obtained from the same patient after several
weeks on frontline antibiotic treatment and was conﬁrmed resis-
tant to INH (tested at 0.2 and 1.0 mg/ml) by the Agar proportion test,
but remained susceptible to the other three ﬁrst line agents (Supp.
table 1). Spoligotyping and insertion sequence (IS)6110 restriction
fragment length polymorphism (RFLP) pattern conﬁrmed C4-INHs
and C1-INHr as a parentemutant pair belonging to the Beijing
genetic subgroup [15]. Clinical isolate C21-INHs also presented
susceptibility to all drugs tested (RIF, INH, pyrazinamide, and
ethambutol) and was obtained from a patient in San Francisco prior
to initiating standard-ﬁrst line anti-tubercular therapy (Supp. table
1). After several weeks on therapy, Clinical isolate C27-INHr was
obtained from the same patient and conﬁrmed resistant to INH by
Agar proportion test (tested as above), but remained susceptible to
the other three ﬁrst-line agents (Supp. table 1). Spoligotyping andIS6110 RFLP conﬁrmed C21-INHs and C27-INHr as a parentemutant
pair belonging to the T genetic subgroup [15].
2.2. Preparation of isolates for WGS
Mtb clinical isolates were plated onto 7H11 þ OADC media and
incubated for 14e28 days at 37 C; growth on plates was monitored
until several isolated colonies appeared.One colony fromeach strain
was selected and inoculated into 100 mL of 7H9þOADCþ 0.1%
Tween-80andallowed togrow for14e21days at 37 Cwith shaking;
fromwhich 3 new100mL cultures for each strainwere inoculated at
an OD600 of 0.05 into 7H9þOADCþ 0.1% Tween-80. Cultures were
allowed to grow at 37 C with shaking until harvested by centrifu-
gation when the OD reads between 0.4 and 0.6 (~48 h). Cell pellets
werewashed three timeswith PBS and processed to isolate genomic
DNA; all samples were stored at 80 C or kept on ice [16]. Library
preparationwas done according to the manufacturer's protocol and
fragments were size selected between 50 and 75bp. Genome
sequencing was performed using the SOLiD 3 (Life Technologies
Corporation, Carlsbad, CA) platform [17].
2.3. katG PCR ampliﬁcation and sequencing
PCR ampliﬁcation for Sanger sequence conﬁrmation of the katG
gene was devised at Colorado State University and utilized a reac-
tion mix that included forward and reverse primers for katG
(125 ng):
Forward 50 CGA TTT TCG GTG CCG TGC GTT TT 30
Reverse 50 CGC CCA GCC ATG CAT GAG CAT TAT 30
Takara Ex Taq® Hot Start DNA polymerase (1.25 U) (TAKARA BIO
INC), a mixture of deoxynucleoside triphosphates (dNTP) (200 mM
each), betaine (1 M) and Mtb gDNA (250 ng).
An initial denaturation step at 94 C for 5min followed by a total
of 40 cycles of ampliﬁcation were performed, with template
denaturation at 94 C for 10 s, primer annealing at 59.5 C for 30 s
and extension at 72 C for 3min. Then a ﬁnal extension at 72 Cwas
done for 6 min. After visualization of the PCR product on an agarose
gel (1.5%), post-PCR cleanup and Sanger sequencing occurred at the
genomic core of the Proteomics and Metabolomics facilities at
Colorado State University.
2.4. Single nucleotide polymorphism detection and annotation
The Lifescope Genome Analysis Software whole genome re-
sequencing pipeline was used with default parameters to map
fragmented reads for each Mtb strain to the H37Rv reference
genome (Supp. table 1) [18,19]. SNPs and Indels were identiﬁed
with thempileup program in samtools version 0.1.18 in conjunction
with bcftools version 0.1.17-dev [19e21]. The following parameters
ﬁltered SNPs and Indels:
1. Minimum SNP mapping quality score >20
2. Minimum of 20 high quality read depth
These ﬁltering criteria are a standard used in numerous WGS
analyses [13,12,6,11,19]. Only SNPs passing the ﬁltering criteriawere
used for downstream analysis. SNPs and Indels were annotated as
intergenic or genic and for amino acid level changes using the
ANNOVAR functional gene annotation software [19,22]. Repeat
regions (PE/PPE and PE-PGRS gene families) that might cause
incorrect read alignments were excluded from further analysis. A
fully automated version of this pipeline is available at https://
github.com/dattagargi/MutationAnalysisPipeline.
Table 2
Number of SNPs in post drug treatment strains in comparison to pre drug treatment
strains.
Comparison Number of SNPs Number of non
synonymous SNPs
C26-RIFs versus C22-RIFr 48 5 (10.4%)
C4-INHs versus C1-INHr 55 8 (14.5%)
C21-INHs versus C27-INHr 17 14 (82.4%)
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A custom Perl script was used to annotate SNPs in genes
associated with Mtb drug resistance and the antibiotic(s) that
each polymorphism confers resistance to using data mined from
the Tuberculosis Drug Resistance Mutation Database
(TBDreaMDB) [23]. SNPs commonly shared with susceptible
strains were considered naturally occurring and non-causal for
resistance. SNPs identiﬁed in known antibiotic resistance deter-
mining genes in phenotypically resistant Mtb strains and not
shared with susceptible strains were investigated further to ﬁnd
drug-resistance conferring SNPs. This required mining the
TBDreaMDB and the TBDB databases for resistance-associated
SNPs [23e25]. The drug resistance proﬁles predicted by the
resistance-associated SNP genotypes were compared with the
phenotypic resistance proﬁles.
2.6. Comparison of SNPs pre and post drug treatment
We compared all annotated SNPs between the pairs of strains
pre and post drug treatment (C26-RIFs vs. C22-RIFr, C4-INHs vs. C1-
INHr, and C21-INHs vs. C27-INHr). We identiﬁed SNPs in the post-
drug treatment resistant strains (C22-RIFr, C1-INHr, and C27-INHr)
that were not in their corresponding pre-drug treatment suscep-
tible strains (C26-RIFs, C4-INHs, and C21-INHs respectively). SNP
calls in the drug resistant strain that were reference calls in the
susceptible strain were considered high quality.
3. Results
The six Mtb strains were grouped according to their drug
resistance proﬁle and genotype (Table 1).
3.1. C26-RIFs versus C22-RIFr
There were 48 SNPs in C22-RIFr that were not present in C26-
RIFs. Of these, there were 5 base changes causing non-
synonymous mutations between the paired isolates (Table 2).
Of the 5 SNPs, one is in rpoB (Rv0667). The SNP, C1349T, resulted
in an amino acid change from serine to leucine (Supp. table 3). This
polymorphism is not mentioned in TBDreaMDB, but is present in
TBDB as a known resistance conferring SNP in H37Rv [4,26,27].
We did a literature survey of the 4 remaining SNPs, and we
found a mutation in the antitoxin encoding gene vapB42 [28].
3.2. C4-INHs versus C1-INHr
There were 55 SNPs in C1-INHr that were not present in C4-SUS.
Of the 55 SNPs, 8 were base changes causing non-synonymous
mutations between the two isolates (Table 2).
Of these 8 SNPs, one is in katG (Rv1908), a gene known to confer
resistance to INH [5]. The SNP is at nucleotide 302 (T302G) causing
a change from leucine to arginine (Supp. table 2), and wasTable 1
Details of the six Mtb strains.
Strain Description of drug susceptibility Mtb genotype
C26-RIFs RIFs Beijing
C22-RIFr RIFr Beijing
C4-INHs INHs Beijing
C1-INHr INHr Beijing
C21-INHs INHs T
C27-INHr INHr Tconﬁrmed using Sanger sequencing. This katG mutation was not
found in any strain in TBDB, thus making it a novel mutation.
We did a literature survey of the 7 remaining SNPS, we
also found a SNP in mazF5, a toxin belonging to the mazEF family
[28].
3.3. C21-INHs versus C27-INHr
There were 17 SNPs in C27-INHr that were not present in C21-
INHs. Of the 17 SNPs, there were 14 SNPs causing non-
synonymous mutations between the two isolates (Table 2).
Of these 14 SNPs, one is in katG (Rv1908). The SNP, T2C, yields a
disruption of the native katG GTG start codon (Supp. table 4), and
was conﬁrmed using Sanger sequencing. This mutation is not found
in any strain in TBDB, but it was reported in an MDR strain from
Russia in 1995 [29].
4. Discussion
We analyzed drug resistance progression to INH and RIF for
three pairs ofMtb (Table 1). Of the pair that gained resistance to RIF
(C26-RIFs, C22-RIFr), C22-RIFr was the post-treatment resistant
strain. Among the unique SNPs identiﬁed in strain C22-RIFr (Supp.
table 3), we found a mutation at nucleotide position 1349 (S450L)
in rpoB, the known target gene for RIF [4,26]. There are several
known drug resistance conferring polymorphisms in this gene,
including T350I, S388L, S450L, D516F/Y, S531L and E639D
[24,25,30e32]. Of these, we found S450L in our drug resistance
progression analysis (Figure 1). Since it is a known mutation for
drug resistance to RIF, S450L acted as a positive control and vali-
dated our genomic pipeline and analysis. Figure 1 depicts a model
of the RIF binding site in rpoB, and the position of the S450L mu-
tation with respect to the binding site [26,33].
To understand progression of resistance to INH in Mtb, we
analyzed SNPs found in two isolate pairs. In most clinical isolates of
Mtb, resistance is due to mutations in katG that may alter myco-
bacterial catalaseeperoxidase activity and at the same time block
prodrug activation [5].Mtb katG is a homodimer of identical 82-kDa
subunits [34]. The N-terminal domain of katG contains a functional
heme-binding site (Figure 2) [35]. Studies have shown that the
dimerization of katG is largely mediated by the ﬁrst 100 amino
acids of the N-terminal domain [35]. There is a lack of information
in literature about the actual binding site of INH to katG [36]. Some
studies have shown that INH can bind in the heme pocket of theOrigin Pre or post drug treatment Citation
Costa Rica Pre Bisson et al. [4]
Costa Rica Post Bisson et al. [4]
Spain Pre Unpublished
Spain Post Unpublished
USA Pre Unpublished
USA Post Unpublished
Figure 1. A) rpoB model (binding site indicated in red). B) A model of the binding site for RIF in rpoB (shown in red). Amino acid position 450, where a mutation was found, shown
in blue [26,33].
Figure 2. A) katG structure (heme binding site highlighted). B) The structure of the heme binding site in katG. Amino acid position 101, a mutation adjacent to the heme binding
site, indicated in magenta [35,37,38].
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channel [36].
In the ﬁrst isolate pair (C4-INHs, C1-INHr), C4-INHs was the pre-
treatment strain susceptible to INH and C1-INHr was the strain post
treatment that developed resistance to the drug. The katGmutation
found between these two isolates, T302G (L101R), has not been
found in previous INH resistance studies, and could contribute to
INH drug resistance observed in the patient isolate. This mutation is
in the second N-terminal domain of katG [35,37]. This SNP causes a
hydrophobic Leucine to mutate to a hydrophilic Arginine. This
amino acid change may change the binding energy or protein
conformation near the active site, preventing INH from binding.
Subsequent katG analysis and phenotypic evaluation demonstrated
ambiguous susceptibility results for C1-INHr, possibly suggesting
reemergence of the susceptible clone. Figure 2 is a model of the
heme-binding site of katG, and the location of the mutation L101R
with respect to the heme-binding site [35,37,38].
From the C21-INHs (susceptible) and C27-INHr (post-treatment
INH resistant) pair, we identiﬁed a mutation at nucleotide position
T2C (f-Met1A) in katG in C27-INHr (Supp. table 4). This mutation
(GTG to GCG) is most likely responsible for conferring resistance toINH in C27-INHr as it is located at the start codon position of katG,
likely disrupting translation initiation at this position. This region is
also responsible for dimerization, as shown by Wilming et al. [35].
Previously, Heym et al. reported this mutation in an INH resistant
TB strain, and provided evidence that the disruption of the native
start codon may result in the use of an alternate upstream start
codon, yielding a larger protein, but without native peroxidase
activity [29].
Among our ﬁndings related to acquired antibiotic resistance, we
also found polymorphisms potentially related toMtb virulence. For
example, we identiﬁed a mutation in the gene encoding for the
toxin mazF5 in C1-INHr (INH-resistant) (Supp. table 2) and in the
gene encoding for the antitoxin vapB42 in C22-RIFr (RIF-resistant)
(Supp. table 3). Toxineantitoxin (TA) systems are small genetic
modules composed of a protein toxin and a protein antitoxin or a
non-coding RNA as an antagonistic antitoxin [39]. Sala et al. and
Georgiades et al. have both hypothesized that the persistence
induced by active toxins could contribute to the pathogenesis of
Mtb, which has been shown to have at least 79 TA systems [28,40].
The mechanisms of these systems as virulence factors have not
been fully elucidated [40].
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We utilized comparative genomics to analyze pre- and post-
drug treatment paired isolates of Mtb and identiﬁed both known
and novel mutations thought to be responsible for progression of
drug resistance. We found a known mutation in rpoB that is
responsible for acquisition of resistance to RIF, as well as a known
but rare mutation in katG affecting the initiation codon. For another
strain that gained resistance to INH, we found a novel mutation
affecting the N-terminus of KatG protein.
The identiﬁcation of a candidate mutation involved in drug
resistance will give further insight into acquired drug resistance
mechanisms to INH. This analysis also improves our understanding
of drug resistance acquisition and progression in TB, and paves the
way for improving diagnostic monitoring for drug-resistant TB.
Finally, this study shows the power of whole genome sequencing
and comparative analysis in identifying possible mutations that
could be supporting the drug resistant phenotype or affecting
ﬁtness.
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